Table 14.3.1.2.2.2
PF-06410293 Protocol B5381001
Summary of Treatment-Emergent Injection Site Reaction Adverse Events by MedDRA System Organ Class, Preferred Term and Maximum CTCAE Grade (All Causalities) - Safety Analysis Set

Number of Subjects Evaluable for AEs	Adalimumab-Pfizer (N=69)					
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total
Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
With Any Adverse Event	1 (1.4)	0	0	0	0	1 (1.4)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	1 (1.4)	0	0	0	0	1 (1.4)
Injection site reaction	1 (1.4)	0	0	0	0	1 (1.4)

For each of Any AEs, SOC or Preferred Term, each subject is only counted once under the highest grade.
MedDRA v16.1 coding dictionary applied.
PFIZER CONFIDENTIAL Source Data: Table 16.2.7.1 Date of SDTM Dataset Creation: 11APR2018 Date of Table Generation: 16MAY2018 (02:45)

PF-06410293 Protocol B5381001
Summary of Treatment-Emergent Injection Site Reaction Adverse Events by MedDRA System Organ Class, Preferred Term and Maximum CTCAE Grade (All Causalities) - Safety Analysis Set

Number of Subjects Evaluable for AEs	Adalimumab-US (N=71)					
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total
Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
With Any Adverse Event	4 (5.6)	1 (1.4)	0	0	0	5 (7.0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	4 (5.6)	1 (1.4)	0	0	0	5 (7.0)
Injection site erythema	2 (2.8)	1 (1.4)	0	0	0	3 (4.2)
Injection site haematoma	1 (1.4)	0	0	0	0	1 (1.4)
Injection site pain	2 (2.8)	0	0	0	0	2 (2.8)

For each of Any AEs, SOC or Preferred Term, each subject is only counted once under the highest grade.
MedDRA v16.1 coding dictionary applied.
PFIZER CONFIDENTIAL Source Data: Table 16.2.7.1 Date of SDTM Dataset Creation: 11APR2018 Date of Table Generation: 16MAY2018 (02:45)

Table 14.3.1.2.2.2
PF-06410293 Protocol B5381001
Summary of Treatment-Emergent Injection Site Reaction Adverse Events by MedDRA System Organ Class, Preferred Term and Maximum CTCAE Grade (All Causalities) - Safety Analysis Set

Number of Subjects Evaluable for AEs	Adalimumab-EU (N=70)					
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total
Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
With Any Adverse Event	0	0	0	0	0	0

For each of Any AEs, SOC or Preferred Term, each subject is only counted once under the highest grade.
MedDRA v16.1 coding dictionary applied.
PFIZER CONFIDENTIAL Source Data: Table 16.2.7.1 Date of SDTM Dataset Creation: 11APR2018 Date of Table Generation: 16MAY2018 (02:45)

Table 14.3.1.2.2.2
PF-06410293 Protocol B5381001
Summary of Treatment-Emergent Injection Site Reaction Adverse Events by MedDRA System Organ Class, Preferred Term and Maximum CTCAE Grade (All Causalities) - Safety Analysis Set

Number of Subjects Evaluable for AEs	Total (N=210)					
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total
Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
With Any Adverse Event	5 (2.4)	1 (0.5)	0	0	0	6 (2.9)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	5 (2.4)	1 (0.5)	0	0	0	6 (2.9)
Injection site erythema	2 (1.0)	1 (0.5)	0	0	0	3 (1.4)
Injection site haematoma	1 (0.5)	0	0	0	0	1 (0.5)
Injection site pain	2 (1.0)	0	0	0	0	2 (1.0)
Injection site reaction	1 (0.5)	0	0	0	0	1 (0.5)

For each of Any AEs, SOC or Preferred Term, each subject is only counted once under the highest grade.
MedDRA v16.1 coding dictionary applied.
PFIZER CONFIDENTIAL Source Data: Table 16.2.7.1 Date of SDTM Dataset Creation: 11APR2018 Date of Table Generation: 16MAY2018 (02:45)

Table 14.3.1.2.3
PF-06410293 Protocol B5381001
Treatment-Emergent Adverse Events by System Organ Class, High Level Group Term and Preferred Term (All Causalities) in >= 5% of Subjects - Safety Analysis Set

Number of Subjects Evaluable for AEs	Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Number (%) of Subjects: by SYSTEM ORGAN CLASS and High Level Group Term and Preferred Term	n (%)	n (%)	n (%)	n (%)
GASTROINTESTINAL DISORDERS	1 (1.4)	2 (2.8)	4 (5.7)	7 (3.3)
Gastrointestinal signs and symptoms	1 (1.4)	2 (2.8)	4 (5.7)	7 (3.3)
Nausea	1 (1.4)	2 (2.8)	4 (5.7)	7 (3.3)
INFECTIONS AND INFESTATIONS	9 (13.0)	8 (11.3)	11 (15.7)	28 (13.3)
Infections - pathogen unspecified	4 (5.8)	4 (5.6)	9 (12.9)	17 (8.1)
Nasopharyngitis	4 (5.8)	4 (5.6)	9 (12.9)	17 (8.1)
Viral infectious disorders	5 (7.2)	5 (7.0)	3 (4.3)	13 (6.2)
Influenza	1 (1.4)	5 (7.0)	1 (1.4)	7 (3.3)
Oral herpes	4 (5.8)	0	2 (2.9)	6 (2.9)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	1 (1.4)	4 (5.6)	2 (2.9)	7 (3.3)
Musculoskeletal and connective tissue disorders NEC	1 (1.4)	4 (5.6)	2 (2.9)	7 (3.3)
Back pain	1 (1.4)	4 (5.6)	2 (2.9)	7 (3.3)
NERVOUS SYSTEM DISORDERS	5 (7.2)	6 (8.5)	12 (17.1)	23 (11.0)
Headaches	5 (7.2)	6 (8.5)	12 (17.1)	23 (11.0)
Headache	5 (7.2)	6 (8.5)	12 (17.1)	23 (11.0)

Subjects are only counted once per treatment for each row.
Includes all data collected since the first dose of study drug.
MedDRA v16.1 coding dictionary applied.
PFIZER CONFIDENTIAL Source Data: Table 16.2.7.1 Date of SDTM Dataset Creation: 11APR2018 Date of Table Generation: 16MAY2018 (02:40)

Table 14.3.1.3.1
PF-06410293 Protocol B5381001
Treatment-Emergent Adverse Events (Treatment Related) - CTC Grade - Safety Analysis Set

	Adalimumab-Pfizer	Adalimumab-US	Adalimumab-EU	Total
Number (%) of Subjects	**n (%)**	**n (%)**	**n (%)**	**n (%)**
Subjects evaluable for adverse events	69	71	70	210
Number of adverse events	19	39	39	97
Subjects with adverse events	15 (21.7)	24 (33.8)	24 (34.3)	63 (30.0)
Subjects with serious adverse events	0	0	0	0
Subjects with Grade 3 or 4 adverse events	0	1 (1.4)	1 (1.4)	2 (1.0)
Subjects with Grade 5 adverse events	0	0	0	0
Subjects discontinued from study due to adverse events	0	0	0	0
Subjects with dose reduced or temporary discontinuation due to adverse events	0	0	0	0

Includes all data collected since the first dose of study drug.
Subjects are counted only once per treatment in each row, except for the Number of Adverse Events.
Serious Adverse Events - according to the investigator's assessment.
MedDRA v16.1 coding dictionary applied.
PFIZER CONFIDENTIAL Source Data: Table 16.2.7.1 Date of SDTM Dataset Creation: 11APR2018 Date of Table Generation: 16MAY2018 (02:39)

Table 14.3.1.3.2.1
PF-06410293 Protocol B5381001
Summary of Treatment-Emergent Adverse Events by MedDRA System Organ Class, Preferred Term, and Maximum CTC Grade (Treatment Related) - Safety Analysis Set

Number of Subjects Evaluable for AEs	Adalimumab-Pfizer (N=69)					
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total
Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
With Any Adverse Event	12 (17.4)	3 (4.3)	0	0	0	15 (21.7)
EAR AND LABYRINTH DISORDERS	1 (1.4)	0	0	0	0	1 (1.4)
Ear pain	1 (1.4)	0	0	0	0	1 (1.4)
GASTROINTESTINAL DISORDERS	4 (5.8)	0	0	0	0	4 (5.8)
Abdominal discomfort	1 (1.4)	0	0	0	0	1 (1.4)
Constipation	1 (1.4)	0	0	0	0	1 (1.4)
Nausea	1 (1.4)	0	0	0	0	1 (1.4)
Toothache	1 (1.4)	0	0	0	0	1 (1.4)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	2 (2.9)	0	0	0	0	2 (2.9)
Fatigue	1 (1.4)	0	0	0	0	1 (1.4)
Injection site reaction	1 (1.4)	0	0	0	0	1 (1.4)
INFECTIONS AND INFESTATIONS	3 (4.3)	1 (1.4)	0	0	0	4 (5.8)
Influenza	0	1 (1.4)	0	0	0	1 (1.4)
Pharyngitis	2 (2.9)	0	0	0	0	2 (2.9)
Rhinitis	1 (1.4)	0	0	0	0	1 (1.4)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	2 (2.9)	0	0	0	0	2 (2.9)
Myalgia	1 (1.4)	0	0	0	0	1 (1.4)
Sensation of heaviness	1 (1.4)	0	0	0	0	1 (1.4)
NERVOUS SYSTEM DISORDERS	2 (2.9)	2 (2.9)	0	0	0	4 (5.8)
Headache	2 (2.9)	2 (2.9)	0	0	0	4 (5.8)
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	1 (1.4)	0	0	0	0	1 (1.4)
Haematospermia	1 (1.4)	0	0	0	0	1 (1.4)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	1 (1.4)	0	0	0	0	1 (1.4)
Sneezing	1 (1.4)	0	0	0	0	1 (1.4)

For each of Any AEs, SOC or Preferred Term, each subject is only counted once under the highest grade.
MedDRA v16.1 coding dictionary applied.
PFIZER CONFIDENTIAL Source Data: Table 16.2.7.1 Date of SDTM Dataset Creation: 11APR2018 Date of Table Generation: 16MAY2018 (02:47)

Table 14.3.1.3.2.1
PF-06410293 Protocol B5381001
Summary of Treatment-Emergent Adverse Events by MedDRA System Organ Class, Preferred Term, and Maximum CTC Grade (Treatment Related) - Safety Analysis Set

Number of Subjects Evaluable for AEs	Adalimumab-US (N=71)					
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total
Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
With Any Adverse Event	21 (29.6)	2 (2.8)	1 (1.4)	0	0	24 (33.8)
GASTROINTESTINAL DISORDERS	7 (9.9)	0	0	0	0	7 (9.9)
Abnormal faeces	1 (1.4)	0	0	0	0	1 (1.4)
Constipation	1 (1.4)	0	0	0	0	1 (1.4)
Diarrhoea	1 (1.4)	0	0	0	0	1 (1.4)
Dyspepsia	1 (1.4)	0	0	0	0	1 (1.4)
Nausea	2 (2.8)	0	0	0	0	2 (2.8)
Oral pain	1 (1.4)	0	0	0	0	1 (1.4)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	7 (9.9)	1 (1.4)	0	0	0	8 (11.3)
Cyst	1 (1.4)	0	0	0	0	1 (1.4)
Fatigue	1 (1.4)	0	0	0	0	1 (1.4)
Feeling hot	1 (1.4)	0	0	0	0	1 (1.4)
Influenza like illness	0	1 (1.4)	0	0	0	1 (1.4)
Injection site erythema	2 (2.8)	1 (1.4)	0	0	0	3 (4.2)
Injection site haematoma	1 (1.4)	0	0	0	0	1 (1.4)
Injection site pain	2 (2.8)	0	0	0	0	2 (2.8)
Non-cardiac chest pain	2 (2.8)	0	0	0	0	2 (2.8)
INFECTIONS AND INFESTATIONS	4 (5.6)	0	1 (1.4)	0	0	5 (7.0)
Gastroenteritis	0	0	1 (1.4)	0	0	1 (1.4)
Influenza	3 (4.2)	0	0	0	0	3 (4.2)
Upper respiratory tract infection	2 (2.8)	0	0	0	0	2 (2.8)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	1 (1.4)	0	0	0	0	1 (1.4)
Muscle spasms	1 (1.4)	0	0	0	0	1 (1.4)
NERVOUS SYSTEM DISORDERS	9 (12.7)	1 (1.4)	0	0	0	10 (14.1)
Cognitive disorder	1 (1.4)	0	0	0	0	1 (1.4)
Dizziness postural	1 (1.4)	0	0	0	0	1 (1.4)
Head discomfort	1 (1.4)	0	0	0	0	1 (1.4)
Headache	4 (5.6)	1 (1.4)	0	0	0	5 (7.0)
Somnolence	2 (2.8)	0	0	0	0	2 (2.8)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	1 (1.4)	1 (1.4)	0	0	0	2 (2.8)

For each of Any AEs, SOC or Preferred Term, each subject is only counted once under the highest grade.
MedDRA v16.1 coding dictionary applied.
PFIZER CONFIDENTIAL Source Data: Table 16.2.7.1 Date of SDTM Dataset Creation: 11APR2018 Date of Table Generation: 16MAY2018 (02:47)

Table 14.3.1.3.2.1
PF-06410293 Protocol B5381001
Summary of Treatment-Emergent Adverse Events by MedDRA System Organ Class, Preferred Term, and Maximum CTC Grade (Treatment Related) - Safety Analysis Set

Number of Subjects Evaluable for AEs	Adalimumab-US (N=71)					
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total
Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Dry skin	1 (1.4)	0	0	0	0	1 (1.4)
Pruritus	0	1 (1.4)	0	0	0	1 (1.4)
Rash	0	1 (1.4)	0	0	0	1 (1.4)

For each of Any AEs, SOC or Preferred Term, each subject is only counted once under the highest grade.
MedDRA v16.1 coding dictionary applied.
PFIZER CONFIDENTIAL Source Data: Table 16.2.7.1 Date of SDTM Dataset Creation: 11APR2018 Date of Table Generation: 16MAY2018 (02:47)

Table 14.3.1.3.2.1
PF-06410293 Protocol B5381001
Summary of Treatment-Emergent Adverse Events by MedDRA System Organ Class, Preferred Term, and Maximum CTC Grade (Treatment Related) - Safety Analysis Set

Number of Subjects Evaluable for AEs	Adalimumab-EU (N=70)					
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total
Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
With Any Adverse Event	17 (24.3)	6 (8.6)	1 (1.4)	0	0	24 (34.3)
GASTROINTESTINAL DISORDERS	9 (12.9)	0	0	0	0	9 (12.9)
Abdominal pain	1 (1.4)	0	0	0	0	1 (1.4)
Abdominal pain lower	1 (1.4)	0	0	0	0	1 (1.4)
Constipation	2 (2.9)	0	0	0	0	2 (2.9)
Diarrhoea	2 (2.9)	0	0	0	0	2 (2.9)
Flatulence	2 (2.9)	0	0	0	0	2 (2.9)
Nausea	3 (4.3)	0	0	0	0	3 (4.3)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	2 (2.9)	1 (1.4)	0	0	0	3 (4.3)
Fatigue	2 (2.9)	0	0	0	0	2 (2.9)
Feeling hot	1 (1.4)	0	0	0	0	1 (1.4)
Influenza like illness	0	1 (1.4)	0	0	0	1 (1.4)
INFECTIONS AND INFESTATIONS	4 (5.7)	3 (4.3)	1 (1.4)	0	0	8 (11.4)
Folliculitis	2 (2.9)	0	0	0	0	2 (2.9)
Gastroenteritis	1 (1.4)	0	0	0	0	1 (1.4)
Influenza	0	1 (1.4)	0	0	0	1 (1.4)
Pharyngitis	0	1 (1.4)	0	0	0	1 (1.4)
Rhinitis	2 (2.9)	0	0	0	0	2 (2.9)
Subcutaneous abscess	0	0	1 (1.4)	0	0	1 (1.4)
Upper respiratory tract infection	0	1 (1.4)	0	0	0	1 (1.4)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	4 (5.7)	0	0	0	0	4 (5.7)
Arthralgia	1 (1.4)	0	0	0	0	1 (1.4)
Back pain	1 (1.4)	0	0	0	0	1 (1.4)
Musculoskeletal chest pain	1 (1.4)	0	0	0	0	1 (1.4)
Musculoskeletal stiffness	1 (1.4)	0	0	0	0	1 (1.4)
NERVOUS SYSTEM DISORDERS	5 (7.1)	1 (1.4)	0	0	0	6 (8.6)
Dizziness	1 (1.4)	0	0	0	0	1 (1.4)
Headache	4 (5.7)	1 (1.4)	0	0	0	5 (7.1)
RENAL AND URINARY DISORDERS	1 (1.4)	0	0	0	0	1 (1.4)
Urine odour abnormal	1 (1.4)	0	0	0	0	1 (1.4)

For each of Any AEs, SOC or Preferred Term, each subject is only counted once under the highest grade.
MedDRA v16.1 coding dictionary applied.
PFIZER CONFIDENTIAL Source Data: Table 16.2.7.1 Date of SDTM Dataset Creation: 11APR2018 Date of Table Generation: 16MAY2018 (02:47)

Table 14.3.1.3.2.1
PF-06410293 Protocol B5381001
Summary of Treatment-Emergent Adverse Events by MedDRA System Organ Class, Preferred Term, and Maximum CTC Grade (Treatment Related) - Safety Analysis Set

Number of Subjects Evaluable for AEs	Adalimumab-EU (N=70)					
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total
Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	1 (1.4)	0	0	0	0	1 (1.4)
Sneezing	1 (1.4)	0	0	0	0	1 (1.4)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	1 (1.4)	1 (1.4)	0	0	0	2 (2.9)
Alopecia	1 (1.4)	0	0	0	0	1 (1.4)
Dermatitis acneiform	0	1 (1.4)	0	0	0	1 (1.4)
Pruritus	0	1 (1.4)	0	0	0	1 (1.4)

For each of Any AEs, SOC or Preferred Term, each subject is only counted once under the highest grade.
MedDRA v16.1 coding dictionary applied.
PFIZER CONFIDENTIAL Source Data: Table 16.2.7.1 Date of SDTM Dataset Creation: 11APR2018 Date of Table Generation: 16MAY2018 (02:47)

Table 14.3.1.3.2.1
PF-06410293 Protocol B5381001
Summary of Treatment-Emergent Adverse Events by MedDRA System Organ Class, Preferred Term, and Maximum CTC Grade (Treatment Related) - Safety Analysis Set

Number of Subjects Evaluable for AEs	Total (N=210)					
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total
Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
With Any Adverse Event	50 (23.8)	11 (5.2)	2 (1.0)	0	0	63 (30.0)
EAR AND LABYRINTH DISORDERS	1 (0.5)	0	0	0	0	1 (0.5)
Ear pain	1 (0.5)	0	0	0	0	1 (0.5)
GASTROINTESTINAL DISORDERS	20 (9.5)	0	0	0	0	20 (9.5)
Abdominal discomfort	1 (0.5)	0	0	0	0	1 (0.5)
Abdominal pain	1 (0.5)	0	0	0	0	1 (0.5)
Abdominal pain lower	1 (0.5)	0	0	0	0	1 (0.5)
Abnormal faeces	1 (0.5)	0	0	0	0	1 (0.5)
Constipation	4 (1.9)	0	0	0	0	4 (1.9)
Diarrhoea	3 (1.4)	0	0	0	0	3 (1.4)
Dyspepsia	1 (0.5)	0	0	0	0	1 (0.5)
Flatulence	2 (1.0)	0	0	0	0	2 (1.0)
Nausea	6 (2.9)	0	0	0	0	6 (2.9)
Oral pain	1 (0.5)	0	0	0	0	1 (0.5)
Toothache	1 (0.5)	0	0	0	0	1 (0.5)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	11 (5.2)	2 (1.0)	0	0	0	13 (6.2)
Cyst	1 (0.5)	0	0	0	0	1 (0.5)
Fatigue	4 (1.9)	0	0	0	0	4 (1.9)
Feeling hot	2 (1.0)	0	0	0	0	2 (1.0)
Influenza like illness	0	2 (1.0)	0	0	0	2 (1.0)
Injection site erythema	2 (1.0)	1 (0.5)	0	0	0	3 (1.4)
Injection site haematoma	1 (0.5)	0	0	0	0	1 (0.5)
Injection site pain	2 (1.0)	0	0	0	0	2 (1.0)
Injection site reaction	1 (0.5)	0	0	0	0	1 (0.5)
Non-cardiac chest pain	2 (1.0)	0	0	0	0	2 (1.0)
INFECTIONS AND INFESTATIONS	11 (5.2)	4 (1.9)	2 (1.0)	0	0	17 (8.1)
Folliculitis	2 (1.0)	0	0	0	0	2 (1.0)
Gastroenteritis	1 (0.5)	0	1 (0.5)	0	0	2 (1.0)
Influenza	3 (1.4)	2 (1.0)	0	0	0	5 (2.4)
Pharyngitis	2 (1.0)	1 (0.5)	0	0	0	3 (1.4)

For each of Any AEs, SOC or Preferred Term, each subject is only counted once under the highest grade.
MedDRA v16.1 coding dictionary applied.
PFIZER CONFIDENTIAL Source Data: Table 16.2.7.1 Date of SDTM Dataset Creation: 11APR2018 Date of Table Generation: 16MAY2018 (02:47)

Table 14.3.1.3.2.1
PF-06410293 Protocol B5381001
Summary of Treatment-Emergent Adverse Events by MedDRA System Organ Class, Preferred Term, and Maximum CTC Grade (Treatment Related) - Safety Analysis Set

Number of Subjects Evaluable for AEs	Total (N=210)					
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total
Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Rhinitis	3 (1.4)	0	0	0	0	3 (1.4)
Subcutaneous abscess	0	0	1 (0.5)	0	0	1 (0.5)
Upper respiratory tract infection	2 (1.0)	1 (0.5)	0	0	0	3 (1.4)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	7 (3.3)	0	0	0	0	7 (3.3)
Arthralgia	1 (0.5)	0	0	0	0	1 (0.5)
Back pain	1 (0.5)	0	0	0	0	1 (0.5)
Muscle spasms	1 (0.5)	0	0	0	0	1 (0.5)
Musculoskeletal chest pain	1 (0.5)	0	0	0	0	1 (0.5)
Musculoskeletal stiffness	1 (0.5)	0	0	0	0	1 (0.5)
Myalgia	1 (0.5)	0	0	0	0	1 (0.5)
Sensation of heaviness	1 (0.5)	0	0	0	0	1 (0.5)
NERVOUS SYSTEM DISORDERS	16 (7.6)	4 (1.9)	0	0	0	20 (9.5)
Cognitive disorder	1 (0.5)	0	0	0	0	1 (0.5)
Dizziness	1 (0.5)	0	0	0	0	1 (0.5)
Dizziness postural	1 (0.5)	0	0	0	0	1 (0.5)
Head discomfort	1 (0.5)	0	0	0	0	1 (0.5)
Headache	10 (4.8)	4 (1.9)	0	0	0	14 (6.7)
Somnolence	2 (1.0)	0	0	0	0	2 (1.0)
RENAL AND URINARY DISORDERS	1 (0.5)	0	0	0	0	1 (0.5)
Urine odour abnormal	1 (0.5)	0	0	0	0	1 (0.5)
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	1 (0.5)	0	0	0	0	1 (0.5)
Haematospermia	1 (0.5)	0	0	0	0	1 (0.5)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	2 (1.0)	0	0	0	0	2 (1.0)
Sneezing	2 (1.0)	0	0	0	0	2 (1.0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	2 (1.0)	2 (1.0)	0	0	0	4 (1.9)
Alopecia	1 (0.5)	0	0	0	0	1 (0.5)
Dermatitis acneiform	0	1 (0.5)	0	0	0	1 (0.5)
Dry skin	1 (0.5)	0	0	0	0	1 (0.5)
Pruritus	0	2 (1.0)	0	0	0	2 (1.0)
Rash	0	1 (0.5)	0	0	0	1 (0.5)

For each of Any AEs, SOC or Preferred Term, each subject is only counted once under the highest grade.
MedDRA v16.1 coding dictionary applied.
PFIZER CONFIDENTIAL Source Data: Table 16.2.7.1 Date of SDTM Dataset Creation: 11APR2018 Date of Table Generation: 16MAY2018 (02:47)

Table 14.3.1.3.2.2
PF-06410293 Protocol B5381001
Summary of Treatment-Emergent Injection Site Reaction Adverse Events by MedDRA System Organ Class, Preferred Term, and Maximum CTC Grade (Treatment Related) - Safety Analysis Set

Number of Subjects Evaluable for AEs	Adalimumab-Pfizer (N=69)					
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total
Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
With Any Adverse Event	1 (1.4)	0	0	0	0	1 (1.4)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	1 (1.4)	0	0	0	0	1 (1.4)
Injection site reaction	1 (1.4)	0	0	0	0	1 (1.4)

For each of Any AEs, SOC or Preferred Term, each subject is only counted once under the highest grade.
MedDRA v16.1 coding dictionary applied.
PFIZER CONFIDENTIAL Source Data: Table 16.2.7.1 Date of SDTM Dataset Creation: 11APR2018 Date of Table Generation: 16MAY2018 (02:48)

Table 14.3.1.3.2.2
PF-06410293 Protocol B5381001
Summary of Treatment-Emergent Injection Site Reaction Adverse Events by MedDRA System Organ Class, Preferred Term, and Maximum CTC Grade (Treatment Related) - Safety Analysis Set

Number of Subjects Evaluable for AEs	Adalimumab-US (N=71)					
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total
Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
With Any Adverse Event	4 (5.6)	1 (1.4)	0	0	0	5 (7.0)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	4 (5.6)	1 (1.4)	0	0	0	5 (7.0)
Injection site erythema	2 (2.8)	1 (1.4)	0	0	0	3 (4.2)
Injection site haematoma	1 (1.4)	0	0	0	0	1 (1.4)
Injection site pain	2 (2.8)	0	0	0	0	2 (2.8)

For each of Any AEs, SOC or Preferred Term, each subject is only counted once under the highest grade.
MedDRA v16.1 coding dictionary applied.
PFIZER CONFIDENTIAL Source Data: Table 16.2.7.1 Date of SDTM Dataset Creation: 11APR2018 Date of Table Generation: 16MAY2018 (02:48)

Table 14.3.1.3.2.2
PF-06410293 Protocol B5381001
Summary of Treatment-Emergent Injection Site Reaction Adverse Events by MedDRA System Organ Class, Preferred Term, and Maximum CTC Grade (Treatment Related) - Safety Analysis Set

Number of Subjects Evaluable for AEs	Adalimumab-EU (N=70)					
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total
Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
With Any Adverse Event	0	0	0	0	0	0

For each of Any AEs, SOC or Preferred Term, each subject is only counted once under the highest grade.
MedDRA v16.1 coding dictionary applied.
PFIZER CONFIDENTIAL Source Data: Table 16.2.7.1 Date of SDTM Dataset Creation: 11APR2018 Date of Table Generation: 16MAY2018 (02:48)

Table 14.3.1.3.2.2
PF-06410293 Protocol B5381001
Summary of Treatment-Emergent Injection Site Reaction Adverse Events by MedDRA System Organ Class, Preferred Term, and Maximum CTC Grade (Treatment Related) - Safety Analysis Set

Number of Subjects Evaluable for AEs	Total (N=210)					
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total
Number (%) of Subjects: by SYSTEM ORGAN CLASS and Preferred Term	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
With Any Adverse Event	5 (2.4)	1 (0.5)	0	0	0	6 (2.9)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	5 (2.4)	1 (0.5)	0	0	0	6 (2.9)
Injection site erythema	2 (1.0)	1 (0.5)	0	0	0	3 (1.4)
Injection site haematoma	1 (0.5)	0	0	0	0	1 (0.5)
Injection site pain	2 (1.0)	0	0	0	0	2 (1.0)
Injection site reaction	1 (0.5)	0	0	0	0	1 (0.5)

For each of Any AEs, SOC or Preferred Term, each subject is only counted once under the highest grade.
MedDRA v16.1 coding dictionary applied.
PFIZER CONFIDENTIAL Source Data: Table 16.2.7.1 Date of SDTM Dataset Creation: 11APR2018 Date of Table Generation: 16MAY2018 (02:48)

Table 14.3.1.3.3
PF-06410293 Protocol B5381001
Treatment-Emergent Adverse Events by System Organ Class, High Level Group Term, and Preferred Term (Treatment Related) in >= 5% of Subjects - Safety Analysis Set

Number of Subjects Evaluable for AEs	Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Number (%) of Subjects: by SYSTEM ORGAN CLASS and High Level Group Term and Preferred Term	n (%)	n (%)	n (%)	n (%)
NERVOUS SYSTEM DISORDERS	4 (5.8)	5 (7.0)	5 (7.1)	14 (6.7)
Headaches	4 (5.8)	5 (7.0)	5 (7.1)	14 (6.7)
Headache	4 (5.8)	5 (7.0)	5 (7.1)	14 (6.7)

Subjects are only counted once per treatment for each row.
Includes all data collected since the first dose of study drug.
MedDRA v16.1 coding dictionary applied.
PFIZER CONFIDENTIAL Source Data: Table 16.2.7.1 Date of SDTM Dataset Creation: 11APR2018 Date of Table Generation: 16MAY2018 (02:42)

Table 14.3.2.2
PF-06410293 Protocol B5381001
Listing of Serious Adverse Events
Reporting Period: Cumulative Through - 12MAR2014

Actual Treatment Group: Adalimumab-EU / 40 mg

Patient Identifier(Country/Sex/Age at Onset(a)/Race/Weight(Kg))								
AER Number	**Suspect Drug(s) / Dose (b)**	**Action Taken (Drug level)**	**Therapy Stop Day (c)**	**Event Onset Day (d)**	**Event Stop Day (e)**	**Verbatim Term/ MedDRA Preferred Term**	**Investigator Causality/ Sponsor Causality**	**Clinical Outcome/ Seriousness**
[redacted]/M[redacted])								
[redacted]	ADALIMUMAB/ 40.00 MG	NOT APPLICABLE	1	38	44	Epigastric Pain/ ABDOMINAL PAIN UPPER	UNRELATED/ UNRELATED	RECOVERED/RESOLVED/ Hospitalization
Number of Cases: 1 Number of Events: 1								
Total Number of Cases: 1 Total Number of Events: 1								

(a) Age at date of SAE onset.
(b) Source of Actual treatment Group or Sequence is PIMS(Phase I Management System).
Source of Suspect Drug is from SDW(Safety Data Warehouse). Dose for treatment(s) at the earliest ONSET date.
(c) Therapy stop day is calculated as OC last active therapy date minus OC first active therapy date plus one.
(d) Onset study day is calculated as SDW onset date minus OC first active therapy date plus one.
(e) Event stop day is calculated as SDW SAE stop date minus OC first active therapy date plus one.
MedDRA v.17.0 coding dictionary applied
PFIZER CONFIDENTIAL Date of SDTM Dataset Creation: 16MAY2018 Date of Table Generation: 16MAY2018 (02:59)

Table 14.3.4.1.1
PF-06410293 Protocol B5381001
Incidence of Laboratory Test Abnormalities (Without Regard to Baseline Abnormality) - Safety Analysis Set

Laboratory Abnormalities: Number of Subjects Evaluable for Laboratory Abnormalities: Number (%) of Subjects with Laboratory Abnormalities:			**Adalimumab-Pfizer** **69** **46 (66.7%)**		**Adalimumab-US** **71** **57 (80.3%)**		**Adalimumab-EU** **70** **55 (78.6%)**		**Total** **210** **158 (75.2%)**	
Group	**Parameter (Units)**	**Primary Criteria**	**N**	**n (%)**	**N**	**n (%)**	**N**	**n (%)**	**N**	**n (%)**
HEMATOLOGY	Hemoglobin (g/dL)	<0.8x LLN	69	0	71	0	70	0	210	0
	Hematocrit (%)	<0.8x LLN	69	0	71	0	70	0	210	0
	Erythrocytes (10^6/mm^3)	<0.8x LLN	69	0	71	0	70	0	210	0
	Ery. Mean Corpuscular Volume (10^-15L)	<0.9x LLN	69	0	71	0	70	0	210	0
		>1.1x ULN	69	0	71	0	70	0	210	0
	Ery. Mean Corpuscular Hemoglobin (pg/cell)	<0.9x LLN	69	0	71	0	70	1 (1.4)	210	1 (0.5)
		>1.1x ULN	69	0	71	0	70	0	210	0
	Ery. Mean Corpuscular HGB Concentration (g/dL)	<0.9x LLN	69	0	71	0	70	0	210	0
		>1.1x ULN	69	0	71	0	70	0	210	0
	Mean Platelet Volume (fL)	<0.9x LLN	69	4 (5.8)	71	9 (12.7)	70	11 (15.7)	210	24 (11.4)
		>1.1x ULN	69	28 (40.6)	71	23 (32.4)	70	26 (37.1)	210	77 (36.7)
	Platelets (10^3/mm^3)	<0.5x LLN	69	0	71	0	70	0	210	0
		>1.75x ULN	69	0	71	0	70	0	210	0
	Leukocytes (10^3/mm^3)	<0.6x LLN	69	0	71	0	70	0	210	0
		>1.5x ULN	69	0	71	0	70	0	210	0
	Lymphocytes (10^3/mm^3)	<0.8x LLN	69	0	71	0	70	0	210	0

NOTE: N = total number of subjects with at least one observation of the given laboratory test while on study treatment or during lag time.
n = number of subjects with a laboratory abnormality meeting specified criteria from the study treatment.
Percentages are displayed for the laboratory tests having a category with greater or equal to 1 evaluable subjects.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:05)

Table 14.3.4.1.1
PF-06410293 Protocol B5381001
Incidence of Laboratory Test Abnormalities (Without Regard to Baseline Abnormality) - Safety Analysis Set

Laboratory Abnormalities: Number of Subjects Evaluable for Laboratory Abnormalities: Number (%) of Subjects with Laboratory Abnormalities:			**Adalimumab-Pfizer** **69** **46 (66.7%)**		**Adalimumab-US** **71** **57 (80.3%)**		**Adalimumab-EU** **70** **55 (78.6%)**		**Total** **210** **158 (75.2%)**	
Group	**Parameter (Units)**	**Primary Criteria**	**N**	**n (%)**	**N**	**n (%)**	**N**	**n (%)**	**N**	**n (%)**
		>1.2x ULN	69	3 (4.3)	71	2 (2.8)	70	2 (2.9)	210	7 (3.3)
	Lymphocytes/Leukocytes (%)	<0.8x LLN	69	4 (5.8)	71	3 (4.2)	70	1 (1.4)	210	8 (3.8)
		>1.2x ULN	69	2 (2.9)	71	4 (5.6)	70	3 (4.3)	210	9 (4.3)
	Neutrophils (10^3/mm^3)	<0.8x LLN	69	1 (1.4)	71	1 (1.4)	70	3 (4.3)	210	5 (2.4)
		>1.2x ULN	69	0	71	0	70	0	210	0
	Neutrophils/Leukocytes (%)	<0.8x LLN	69	3 (4.3)	71	0	70	3 (4.3)	210	6 (2.9)
		>1.2x ULN	69	0	71	0	70	0	210	0
	Basophils (10^3/mm^3)	>1.2x ULN	69	0	71	0	70	0	210	0
	Basophils/Leukocytes (%)	>1.2x ULN	69	4 (5.8)	71	5 (7.0)	70	5 (7.1)	210	14 (6.7)
	Eosinophils (10^3/mm^3)	>1.2x ULN	69	5 (7.2)	71	5 (7.0)	70	7 (10.0)	210	17 (8.1)
	Eosinophils/Leukocytes (%)	>1.2x ULN	69	5 (7.2)	71	8 (11.3)	70	9 (12.9)	210	22 (10.5)
	Monocytes (10^3/mm^3)	>1.2x ULN	69	4 (5.8)	71	8 (11.3)	70	3 (4.3)	210	15 (7.1)
	Monocytes/Leukocytes (%)	>1.2x ULN	69	5 (7.2)	71	7 (9.9)	70	4 (5.7)	210	16 (7.6)
	PTT (sec)	>1.1x ULN	0	0	0	0	1	0	1	0
	Prothrombin Time (sec)	>1.1x ULN	0	0	0	0	1	0	1	0

NOTE: N = total number of subjects with at least one observation of the given laboratory test while on study treatment or during lag time.
n = number of subjects with a laboratory abnormality meeting specified criteria from the study treatment.
Percentages are displayed for the laboratory tests having a category with greater or equal to 1 evaluable subjects.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:05)

Table 14.3.4.1.1
PF-06410293 Protocol B5381001
Incidence of Laboratory Test Abnormalities (Without Regard to Baseline Abnormality) - Safety Analysis Set

Laboratory Abnormalities: Number of Subjects Evaluable for Laboratory Abnormalities: Number (%) of Subjects with Laboratory Abnormalities:			**Adalimumab-Pfizer** **69** **46 (66.7%)**		**Adalimumab-US** **71** **57 (80.3%)**		**Adalimumab-EU** **70** **55 (78.6%)**		**Total** **210** **158 (75.2%)**	
Group	**Parameter (Units)**	**Primary Criteria**	**N**	**n (%)**	**N**	**n (%)**	**N**	**n (%)**	**N**	**n (%)**
	Prothrombin Intl. Normalized Ratio	>1.1x ULN	0	0	0	0	1	0	1	0
CLINICAL CHEMISTRY	Bilirubin (mg/dL)	>1.5x ULN	69	3 (4.3)	71	1 (1.4)	70	1 (1.4)	210	5 (2.4)
	Aspartate Aminotransferase (U/L)	>3.0x ULN	69	0	71	1 (1.4)	70	2 (2.9)	210	3 (1.4)
	Alanine Aminotransferase (U/L)	>3.0x ULN	69	0	71	1 (1.4)	70	2 (2.9)	210	3 (1.4)
	Alkaline Phosphatase (U/L)	>3.0x ULN	69	0	71	0	70	0	210	0
	Protein (g/dL)	<0.8x LLN	69	0	71	0	70	0	210	0
		>1.2x ULN	69	0	71	0	70	0	210	0
	Albumin (g/dL)	<0.8x LLN	69	0	71	0	70	0	210	0
		>1.2x ULN	69	0	71	0	70	0	210	0
	Blood Urea Nitrogen (mg/dL)	>1.3x ULN	69	0	71	1 (1.4)	70	2 (2.9)	210	3 (1.4)
	Urea (mg/dL)	>1.3x ULN	41	1 (2.4)	42	1 (2.4)	42	3 (7.1)	125	5 (4.0)
	Creatinine (mg/dL)	>1.3x ULN	69	0	71	0	70	0	210	0
	Urate (mg/dL)	>1.2x ULN	69	0	71	2 (2.8)	70	0	210	2 (1.0)
	Sodium (Meq/L)	<0.95x LLN	69	0	71	0	70	0	210	0
		>1.05x ULN	69	0	71	0	70	0	210	0
	Potassium (Meq/L)	<0.9x LLN	69	0	71	0	70	1 (1.4)	210	1 (0.5)

NOTE: N = total number of subjects with at least one observation of the given laboratory test while on study treatment or during lag time.
n = number of subjects with a laboratory abnormality meeting specified criteria from the study treatment.
Percentages are displayed for the laboratory tests having a category with greater or equal to 1 evaluable subjects.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:05)

Table 14.3.4.1.1
PF-06410293 Protocol B5381001
Incidence of Laboratory Test Abnormalities (Without Regard to Baseline Abnormality) - Safety Analysis Set

Laboratory Abnormalities: Number of Subjects Evaluable for Laboratory Abnormalities: Number (%) of Subjects with Laboratory Abnormalities:			**Adalimumab-Pfizer** **69** **46 (66.7%)**		**Adalimumab-US** **71** **57 (80.3%)**		**Adalimumab-EU** **70** **55 (78.6%)**		**Total** **210** **158 (75.2%)**	
Group	**Parameter (Units)**	**Primary Criteria**	**N**	**n (%)**	**N**	**n (%)**	**N**	**n (%)**	**N**	**n (%)**
		>1.1x ULN	69	1 (1.4)	71	0	70	0	210	1 (0.5)
	Chloride (Meq/L)	<0.9x LLN	69	0	71	0	70	0	210	0
		>1.1x ULN	69	0	71	0	70	0	210	0
	Calcium (mg/dL)	<0.9x LLN	69	0	71	0	70	0	210	0
		>1.1x ULN	69	0	71	0	70	0	210	0
	Bicarbonate (Meq/L)	<0.9x LLN	69	0	71	0	70	0	210	0
		>1.1x ULN	69	0	71	1 (1.4)	70	1 (1.4)	210	2 (1.0)
	Hemoglobin A1C (%)	>1.3x ULN	0	0	1	0	0	0	1	0
	Glucose (mg/dL)	<0.6x LLN	69	0	71	0	70	0	210	0
		>1.5x ULN	69	0	71	1 (1.4)	70	0	210	1 (0.5)
URINALYSIS	Specific Gravity	<1.003	42	0	42	0	43	0	127	0
		>1.030	42	0	42	0	43	0	127	0
	URINE Glucose	>=1	69	0	71	0	70	0	210	0
	Ketones	>=1	69	1 (1.4)	71	3 (4.2)	70	3 (4.3)	210	7 (3.3)
	URINE Protein	>=1	69	1 (1.4)	71	0	70	0	210	1 (0.5)
	URINE Hemoglobin	>=1	69	3 (4.3)	71	5 (7.0)	70	5 (7.1)	210	13 (6.2)

NOTE: N = total number of subjects with at least one observation of the given laboratory test while on study treatment or during lag time.
n = number of subjects with a laboratory abnormality meeting specified criteria from the study treatment.
Percentages are displayed for the laboratory tests having a category with greater or equal to 1 evaluable subjects.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:05)

Table 14.3.4.1.1
PF-06410293 Protocol B5381001
Incidence of Laboratory Test Abnormalities (Without Regard to Baseline Abnormality) - Safety Analysis Set

Laboratory Abnormalities: Number of Subjects Evaluable for Laboratory Abnormalities: Number (%) of Subjects with Laboratory Abnormalities:			**Adalimumab-Pfizer** **69** **46 (66.7%)**		**Adalimumab-US** **71** **57 (80.3%)**		**Adalimumab-EU** **70** **55 (78.6%)**		**Total** **210** **158 (75.2%)**	
Group	**Parameter (Units)**	**Primary Criteria**	**N**	**n (%)**	**N**	**n (%)**	**N**	**n (%)**	**N**	**n (%)**
	Urobilinogen	>=1	69	1 (1.4)	71	3 (4.2)	70	3 (4.3)	210	7 (3.3)
	URINE Bilirubin	>=1	69	2 (2.9)	71	4 (5.6)	70	5 (7.1)	210	11 (5.2)
	Nitrite	>=1	69	0	71	0	70	0	210	0
	Leukocyte Esterase	>=1	28	0	30	0	29	0	87	0
	URINE Erythrocytes (/HPF)	>=20	5	0	7	1 (14.3)	15	0	27	1 (3.7)
	URINE Leukocytes (/HPF)	>=20	5	0	7	0	12	0	24	0
	Epithelial Cells (/LPF)	>=6	0	0	1	0	1	0	2	0
	Granular Casts (/LPF)	>1	0	0	1	0	1	0	2	0
	Hyaline Casts (/LPF)	>1	1	1 (100.0)	1	0	2	0	4	1 (25.0)
	Bacteria	>20	3	0	6	0	7	0	16	0

NOTE: N = total number of subjects with at least one observation of the given laboratory test while on study treatment or during lag time.
n = number of subjects with a laboratory abnormality meeting specified criteria from the study treatment.
Percentages are displayed for the laboratory tests having a category with greater or equal to 1 evaluable subjects.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:05)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	14.66	14.99	14.94	14.86
	SD	0.829	0.920	0.936	0.904
	Median	14.70	15.00	15.00	14.90
	Min	12.90	12.80	11.70	11.70
	Max	16.30	17.40	16.90	17.40
Day4	n	69	71	70	210
	Mean	15.19	15.34	15.21	15.25
	SD	0.758	0.925	0.926	0.873
	Median	15.10	15.30	15.20	15.20
	Min	13.70	12.40	12.40	12.40
	Max	17.20	17.70	17.10	17.70
Day8	n	69	71	70	210
	Mean	15.18	15.40	15.30	15.30
	SD	0.745	0.968	0.864	0.865
	Median	15.10	15.50	15.30	15.30
	Min	13.40	12.30	12.40	12.30
	Max	17.40	18.00	17.20	18.00

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	14.72	15.02	14.85	14.86
	SD	0.862	0.934	0.952	0.921
	Median	14.70	15.10	14.90	14.90
	Min	12.90	11.50	11.50	11.50
	Max	16.60	17.30	16.80	17.30
Day29	n	67	70	70	207
	Mean	14.81	15.12	15.05	14.99
	SD	0.829	0.864	0.913	0.875
	Median	14.70	15.10	15.10	15.00
	Min	13.10	12.30	12.10	12.10
	Max	17.50	17.70	16.90	17.70
Day43	n	67	71	69	207
	Mean	15.03	15.11	14.99	15.04
	SD	0.858	0.957	0.973	0.929
	Median	14.90	15.20	15.10	15.10
	Min	12.80	12.10	12.50	12.10
	Max	17.10	17.50	18.20	18.20

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	14.96	15.22	15.18	15.12
	SD	0.771	0.852	0.893	0.845
	Median	14.90	15.10	15.30	15.00
	Min	13.00	13.50	12.70	12.70
	Max	17.60	18.10	17.40	18.10

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	42.79	43.57	43.53	43.30
	SD	2.424	2.621	2.841	2.647
	Median	43.00	43.90	43.15	43.00
	Min	37.00	37.00	36.10	36.10
	Max	47.30	50.00	49.10	50.00
Day4	n	69	71	70	210
	Mean	44.40	44.60	44.46	44.49
	SD	2.548	2.683	2.555	2.586
	Median	44.60	44.30	44.00	44.30
	Min	39.00	38.00	38.30	38.00
	Max	49.60	51.50	50.90	51.50
Day8	n	69	71	70	210
	Mean	44.39	44.93	44.83	44.72
	SD	2.499	2.751	2.489	2.582
	Median	44.10	45.00	45.00	44.85
	Min	39.40	39.60	39.00	39.00
	Max	50.30	52.50	50.20	52.50

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	43.27	43.91	43.35	43.52
	SD	2.606	2.651	2.769	2.679
	Median	43.00	44.00	44.00	43.85
	Min	38.90	36.80	35.70	35.70
	Max	50.00	50.60	49.00	50.60
Day29	n	67	70	70	207
	Mean	43.38	44.20	43.96	43.85
	SD	2.546	2.396	2.600	2.526
	Median	43.20	44.45	44.00	44.00
	Min	38.00	38.90	36.80	36.80
	Max	51.00	50.10	49.20	51.00
Day43	n	67	71	69	207
	Mean	44.10	44.21	43.78	44.03
	SD	2.493	2.756	2.689	2.644
	Median	44.00	44.00	44.00	44.00
	Min	38.50	38.00	37.60	37.60
	Max	51.00	52.00	53.00	53.00

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	43.78	44.27	43.99	44.02
	SD	2.455	2.460	2.500	2.468
	Median	43.90	44.00	44.00	44.00
	Min	39.20	39.00	37.60	37.60
	Max	49.00	51.00	49.80	51.00

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	4.91	4.99	5.04	4.98
	SD	0.343	0.405	0.402	0.386
	Median	4.89	4.99	5.02	4.98
	Min	4.17	4.11	4.14	4.11
	Max	5.69	5.96	6.09	6.09
Day4	n	69	71	70	210
	Mean	5.09	5.10	5.14	5.11
	SD	0.347	0.419	0.386	0.384
	Median	5.09	5.07	5.17	5.09
	Min	4.28	4.22	4.10	4.10
	Max	5.79	6.09	5.99	6.09
Day8	n	69	71	70	210
	Mean	5.08	5.13	5.17	5.13
	SD	0.339	0.399	0.381	0.374
	Median	5.02	5.15	5.14	5.10
	Min	4.31	4.35	4.22	4.22
	Max	5.92	6.24	6.23	6.24

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	4.95	5.01	5.01	4.99
	SD	0.368	0.415	0.371	0.385
	Median	4.93	5.02	4.95	4.94
	Min	4.13	4.11	3.95	3.95
	Max	5.80	6.19	5.92	6.19
Day29	n	67	70	70	207
	Mean	4.97	5.04	5.07	5.03
	SD	0.363	0.387	0.360	0.371
	Median	4.93	5.05	5.03	5.01
	Min	4.22	3.99	4.37	3.99
	Max	5.74	5.97	6.04	6.04
Day43	n	67	71	69	207
	Mean	5.05	5.05	5.06	5.05
	SD	0.356	0.426	0.384	0.389
	Median	5.03	5.05	5.03	5.03
	Min	4.27	4.02	4.15	4.02
	Max	6.00	6.33	6.09	6.33

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	5.04	5.08	5.11	5.08
	SD	0.353	0.398	0.405	0.385
	Median	5.02	5.09	5.11	5.09
	Min	4.39	4.33	4.25	4.25
	Max	5.80	6.12	6.41	6.41

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	87.24	87.50	86.49	87.08
	SD	3.831	4.815	4.123	4.282
	Median	88.00	87.30	86.20	87.00
	Min	78.30	78.00	75.40	75.40
	Max	95.20	99.60	94.60	99.60
Day4	n	69	71	70	210
	Mean	87.30	87.71	86.59	87.21
	SD	3.686	4.947	4.212	4.323
	Median	87.90	87.30	87.00	87.00
	Min	79.20	78.00	75.20	75.20
	Max	95.30	101.00	95.00	101.00
Day8	n	69	71	70	210
	Mean	87.39	87.85	86.88	87.37
	SD	3.754	4.852	4.297	4.327
	Median	88.00	88.00	87.00	87.35
	Min	79.20	78.00	74.90	74.90
	Max	95.20	98.80	96.00	98.80

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	87.59	87.89	86.79	87.43
	SD	3.772	4.825	4.123	4.275
	Median	87.65	87.80	87.00	87.15
	Min	79.20	78.00	74.50	74.50
	Max	95.00	101.00	94.50	101.00
Day29	n	67	70	70	207
	Mean	87.56	87.92	86.94	87.47
	SD	3.765	4.815	4.070	4.245
	Median	88.00	88.00	87.00	88.00
	Min	79.20	78.00	74.70	74.70
	Max	95.40	98.30	94.10	98.30
Day43	n	67	71	69	207
	Mean	87.46	87.78	86.70	87.31
	SD	3.744	4.884	4.039	4.265
	Median	88.00	87.50	87.00	87.50
	Min	78.10	78.00	75.80	75.80
	Max	95.00	99.20	94.00	99.20

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	86.93	87.37	86.27	86.86
	SD	4.071	5.096	4.121	4.461
	Median	87.00	87.00	87.00	87.00
	Min	76.10	77.60	75.30	75.30
	Max	97.80	99.00	95.00	99.00

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	29.86	30.12	29.75	29.91
	SD	1.677	2.020	1.809	1.840
	Median	30.00	30.00	30.00	30.00
	Min	25.90	25.50	24.30	24.30
	Max	33.10	35.00	32.50	35.00
Day4	n	69	71	70	210
	Mean	29.90	30.19	29.68	29.93
	SD	1.574	1.877	1.807	1.763
	Median	30.00	30.10	30.00	30.00
	Min	26.00	25.40	23.80	23.80
	Max	33.00	34.00	32.10	34.00
Day8	n	69	71	70	210
	Mean	29.93	30.13	29.66	29.91
	SD	1.640	1.776	1.732	1.720
	Median	30.00	30.00	30.00	30.00
	Min	26.10	25.80	23.80	23.80
	Max	33.00	34.10	32.30	34.10

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	29.79	30.11	29.68	29.86
	SD	1.611	1.893	1.774	1.766
	Median	30.00	30.00	30.00	30.00
	Min	26.20	25.90	24.50	24.50
	Max	32.80	34.40	32.20	34.40
Day29	n	67	70	70	207
	Mean	29.91	30.10	29.78	29.93
	SD	1.594	1.931	1.669	1.736
	Median	30.00	30.00	30.00	30.00
	Min	26.10	25.80	24.50	24.50
	Max	33.10	34.20	32.40	34.20
Day43	n	67	71	69	207
	Mean	29.83	30.01	29.70	29.85
	SD	1.536	1.835	1.699	1.694
	Median	30.00	30.00	30.00	30.00
	Min	26.20	25.40	24.60	24.60
	Max	33.00	34.10	33.00	34.10

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.

PF-06410293 Protocol B5381001
Laboratory Data Absolute Values - Safety Analysis Set
Parameter: Ery. Mean Corpuscular Hemoglobin (pg/cell)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	29.70	30.05	29.80	29.85
	SD	1.557	1.891	1.757	1.740
	Median	30.00	30.00	30.00	30.00
	Min	25.90	26.00	24.60	24.60
	Max	32.30	35.00	33.50	35.00

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	34.28	34.37	34.34	34.33
	SD	1.114	1.267	1.226	1.200
	Median	34.40	34.50	34.50	34.50
	Min	32.00	30.50	32.00	30.50
	Max	36.90	36.90	37.50	37.50
Day4	n	69	71	70	210
	Mean	34.24	34.40	34.22	34.29
	SD	1.087	1.142	1.221	1.149
	Median	34.20	34.40	34.25	34.30
	Min	31.90	30.60	31.60	30.60
	Max	36.10	36.80	36.80	36.80
Day8	n	69	71	70	210
	Mean	34.22	34.33	34.14	34.23
	SD	1.146	1.109	1.094	1.114
	Median	34.30	34.40	34.25	34.30
	Min	32.00	31.10	31.60	31.10
	Max	36.30	36.60	35.90	36.60

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

PF-06410293 Protocol B5381001
Laboratory Data Absolute Values - Safety Analysis Set
Parameter: Ery. Mean Corpuscular HGB Concentration (g/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	34.05	34.22	34.21	34.16
	SD	0.947	1.091	1.006	1.016
	Median	34.10	34.20	34.30	34.20
	Min	31.40	31.30	31.70	31.30
	Max	36.00	36.90	36.20	36.90
Day29	n	67	70	70	207
	Mean	34.15	34.23	34.23	34.21
	SD	0.991	0.960	0.797	0.915
	Median	34.20	34.20	34.40	34.30
	Min	32.10	31.60	32.10	31.60
	Max	36.20	36.70	35.60	36.70
Day43	n	67	71	69	207
	Mean	34.12	34.24	34.26	34.21
	SD	0.939	0.883	0.841	0.886
	Median	34.20	34.20	34.30	34.20
	Min	32.30	31.60	31.50	31.50
	Max	36.80	36.20	35.60	36.80

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

PF-06410293 Protocol B5381001
Laboratory Data Absolute Values - Safety Analysis Set
Parameter: Ery. Mean Corpuscular HGB Concentration (g/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	34.19	34.39	34.49	34.36
	SD	1.053	1.026	0.970	1.020
	Median	34.20	34.40	34.50	34.40
	Min	31.90	32.30	32.00	31.90
	Max	36.70	36.60	37.10	37.10

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.

Table 14.3.4.1.2.1
PF-06410293 Protocol B5381001
Laboratory Data Absolute Values - Safety Analysis Set
Parameter: Mean Platelet Volume (fL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	8.41	8.33	8.16	8.30
	SD	1.425	1.576	1.392	1.464
	Median	8.10	8.50	8.25	8.30
	Min	5.30	5.60	5.40	5.30
	Max	11.30	13.00	10.70	13.00
Day4	n	69	71	70	210
	Mean	8.72	8.56	8.38	8.55
	SD	1.725	1.659	1.508	1.631
	Median	8.60	8.70	8.35	8.60
	Min	5.30	5.50	5.20	5.20
	Max	13.80	13.20	11.30	13.80
Day8	n	69	71	70	210
	Mean	8.65	8.38	8.35	8.46
	SD	1.524	1.501	1.511	1.511
	Median	8.40	8.40	8.35	8.40
	Min	5.40	5.40	5.70	5.40
	Max	12.90	12.40	12.20	12.90

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	8.79	8.51	8.32	8.54
	SD	1.599	1.755	1.511	1.630
	Median	8.75	8.50	8.40	8.60
	Min	5.00	5.20	5.70	5.00
	Max	13.60	13.30	11.40	13.60
Day29	n	67	70	70	207
	Mean	8.79	8.61	8.34	8.58
	SD	1.638	1.813	1.595	1.687
	Median	9.00	8.80	8.55	8.80
	Min	5.10	5.40	4.90	4.90
	Max	12.30	13.30	11.50	13.30
Day43	n	67	71	69	207
	Mean	8.72	8.57	8.30	8.53
	SD	1.761	1.856	1.694	1.772
	Median	8.80	8.80	8.60	8.70
	Min	5.30	5.20	5.00	5.00
	Max	13.30	14.40	11.80	14.40

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	8.71	8.45	8.26	8.47
	SD	1.840	1.797	1.572	1.742
	Median	8.60	8.60	8.60	8.60
	Min	5.00	5.30	5.40	5.00
	Max	12.80	14.40	11.50	14.40

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	235.26	238.08	244.24	239.21
	SD	51.670	55.548	52.398	53.128
	Median	237.00	228.00	236.00	236.00
	Min	146.00	121.00	151.00	121.00
	Max	442.00	385.00	363.00	442.00
Day4	n	69	71	70	210
	Mean	230.55	238.23	241.34	236.74
	SD	50.599	53.940	53.325	52.600
	Median	228.00	238.00	239.50	234.00
	Min	117.00	130.00	155.00	117.00
	Max	372.00	386.00	374.00	386.00
Day8	n	69	71	70	210
	Mean	230.77	236.44	246.64	237.98
	SD	47.114	56.826	62.649	56.059
	Median	222.00	236.00	236.00	231.00
	Min	107.00	130.00	136.00	107.00
	Max	336.00	413.00	401.00	413.00

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	231.16	230.13	239.83	233.68
	SD	51.438	58.177	52.614	54.123
	Median	234.00	223.00	230.00	226.00
	Min	135.00	121.00	140.00	121.00
	Max	380.00	456.00	383.00	456.00
Day29	n	67	70	70	207
	Mean	228.06	234.66	237.70	233.55
	SD	52.505	57.537	51.776	53.908
	Median	222.00	224.00	229.00	226.00
	Min	146.00	116.00	158.00	116.00
	Max	367.00	422.00	388.00	422.00
Day43	n	67	71	69	207
	Mean	238.16	240.39	244.26	240.96
	SD	56.331	56.021	55.845	55.847
	Median	237.00	234.00	231.00	235.00
	Min	121.00	136.00	146.00	121.00
	Max	460.00	407.00	463.00	463.00

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	233.90	235.01	246.00	238.31
	SD	55.561	56.013	57.249	56.278
	Median	228.00	231.00	239.00	231.50
	Min	143.00	119.00	144.00	119.00
	Max	419.00	437.00	416.00	437.00

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	6.26	6.60	6.44	6.43
	SD	1.397	1.605	1.447	1.486
	Median	6.20	6.30	6.20	6.25
	Min	3.30	3.10	3.30	3.10
	Max	10.10	10.40	9.20	10.40
Day4	n	69	71	70	210
	Mean	5.68	5.92	5.81	5.81
	SD	1.260	1.336	1.306	1.299
	Median	5.70	5.80	5.65	5.75
	Min	3.40	2.60	3.50	2.60
	Max	9.00	9.40	9.60	9.60
Day8	n	69	71	70	210
	Mean	5.74	5.96	5.87	5.86
	SD	1.179	1.381	1.360	1.308
	Median	5.60	6.00	5.70	5.70
	Min	3.70	2.60	2.80	2.60
	Max	9.20	10.10	9.30	10.10

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

Table 14.3.4.1.2.1
PF-06410293 Protocol B5381001
Laboratory Data Absolute Values - Safety Analysis Set
Parameter: Leukocytes (10^3/mm^3)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	5.88	6.06	5.92	5.96
	SD	1.418	1.437	1.531	1.458
	Median	5.90	6.00	5.70	5.90
	Min	3.20	3.10	3.10	3.10
	Max	9.60	9.90	10.40	10.40
Day29	n	67	70	70	207
	Mean	6.05	5.78	5.95	5.93
	SD	1.493	1.314	1.491	1.431
	Median	5.70	5.65	5.80	5.70
	Min	3.70	2.50	3.20	2.50
	Max	10.90	8.30	10.20	10.90
Day43	n	67	71	69	207
	Mean	6.05	6.03	6.00	6.03
	SD	1.559	1.358	1.582	1.494
	Median	5.80	6.00	6.00	5.90
	Min	4.10	3.30	3.00	3.00
	Max	11.30	10.60	10.00	11.30

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	6.12	6.15	6.20	6.16
	SD	1.495	1.435	1.509	1.473
	Median	6.20	6.10	6.20	6.10
	Min	3.50	3.30	3.30	3.30
	Max	11.90	9.90	9.90	11.90

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

Table 14.3.4.1.2.1
PF-06410293 Protocol B5381001
Laboratory Data Absolute Values - Safety Analysis Set
Parameter: Lymphocytes (10^3/mm^3)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	1.93	1.97	2.00	1.97
	SD	0.520	0.547	0.429	0.500
	Median	1.87	1.93	2.00	1.94
	Min	0.75	0.80	1.00	0.75
	Max	3.88	3.30	3.34	3.88
Day4	n	69	71	70	210
	Mean	2.17	2.25	2.21	2.21
	SD	0.564	0.591	0.479	0.545
	Median	2.10	2.20	2.20	2.20
	Min	1.20	1.22	1.33	1.20
	Max	4.10	3.90	3.80	4.10
Day8	n	69	71	70	210
	Mean	2.14	2.17	2.23	2.18
	SD	0.541	0.594	0.503	0.546
	Median	2.10	2.18	2.20	2.18
	Min	1.10	0.90	1.40	0.90
	Max	3.50	3.70	4.10	4.10

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	2.15	2.13	2.10	2.12
	SD	0.579	0.596	0.459	0.546
	Median	2.07	2.10	2.10	2.10
	Min	1.10	1.10	1.16	1.10
	Max	3.51	4.50	3.28	4.50
Day29	n	67	70	70	207
	Mean	2.09	2.01	2.05	2.05
	SD	0.622	0.574	0.435	0.546
	Median	2.00	1.91	2.01	2.00
	Min	0.85	0.99	1.10	0.85
	Max	3.80	3.70	3.00	3.80
Day43	n	67	71	69	207
	Mean	2.04	1.96	2.00	2.00
	SD	0.512	0.494	0.520	0.507
	Median	1.97	1.90	2.00	1.92
	Min	1.01	1.08	1.03	1.01
	Max	3.30	3.10	4.14	4.14

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	1.98	1.90	1.92	1.93
	SD	0.575	0.547	0.405	0.513
	Median	1.94	1.80	1.90	1.87
	Min	1.00	0.90	1.10	0.90
	Max	3.50	3.40	3.50	3.50

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	31.54	30.73	31.92	31.40
	SD	7.827	8.416	7.583	7.930
	Median	31.10	30.10	31.30	30.80
	Min	13.10	14.10	17.40	13.10
	Max	51.80	52.80	47.50	52.80
Day4	n	69	71	70	210
	Mean	38.51	38.62	38.89	38.67
	SD	7.127	8.558	7.804	7.822
	Median	37.50	37.20	38.80	37.90
	Min	22.90	19.80	23.80	19.80
	Max	59.80	57.30	61.00	61.00
Day8	n	69	71	70	210
	Mean	37.44	36.86	38.77	37.68
	SD	7.293	8.042	7.299	7.563
	Median	36.20	36.10	39.35	37.60
	Min	21.50	20.80	23.00	20.80
	Max	64.40	56.20	57.00	64.40

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	37.08	35.56	36.77	36.46
	SD	7.605	7.417	8.843	7.965
	Median	35.80	36.10	37.30	36.65
	Min	17.90	19.30	15.60	15.60
	Max	51.60	55.50	53.10	55.50
Day29	n	67	70	70	207
	Mean	35.18	34.93	35.80	35.30
	SD	8.865	7.204	9.233	8.441
	Median	35.30	35.85	36.35	35.50
	Min	12.20	21.30	17.50	12.20
	Max	60.20	53.70	56.50	60.20
Day43	n	67	71	69	207
	Mean	34.47	33.01	34.59	34.01
	SD	7.717	7.441	8.559	7.912
	Median	34.90	33.00	33.70	33.70
	Min	15.00	16.00	15.90	15.00
	Max	60.20	56.60	51.50	60.20

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	32.99	31.27	32.29	32.18
	SD	8.217	6.603	8.038	7.642
	Median	32.90	31.80	31.45	32.05
	Min	12.80	14.40	18.40	12.80
	Max	54.60	43.90	51.30	54.60

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	3.62	3.84	3.72	3.73
	SD	1.109	1.390	1.280	1.263
	Median	3.50	3.73	3.51	3.55
	Min	1.70	1.60	1.70	1.60
	Max	6.70	7.37	7.00	7.37
Day4	n	69	71	70	210
	Mean	2.80	2.92	2.87	2.86
	SD	0.797	0.981	1.010	0.932
	Median	2.84	2.97	2.82	2.84
	Min	1.10	0.90	1.20	0.90
	Max	5.00	5.70	5.60	5.70
Day8	n	69	71	70	210
	Mean	2.91	3.05	2.91	2.96
	SD	0.817	1.010	1.008	0.948
	Median	2.80	3.03	2.75	2.81
	Min	1.30	1.10	1.10	1.10
	Max	6.19	6.60	5.80	6.60

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	2.97	3.15	3.07	3.07
	SD	1.011	1.068	1.296	1.129
	Median	2.85	2.97	2.76	2.90
	Min	1.30	1.36	1.20	1.20
	Max	6.00	6.85	6.90	6.90
Day29	n	67	70	70	207
	Mean	3.16	3.02	3.12	3.10
	SD	1.130	0.916	1.292	1.119
	Median	2.89	3.01	3.07	2.99
	Min	1.20	1.10	1.00	1.00
	Max	6.90	5.70	7.55	7.55
Day43	n	67	71	69	207
	Mean	3.25	3.29	3.21	3.25
	SD	1.230	1.058	1.237	1.171
	Median	3.00	3.15	3.18	3.10
	Min	1.30	1.60	1.00	1.00
	Max	7.40	6.20	6.40	7.40

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	3.41	3.45	3.48	3.45
	SD	1.240	1.052	1.293	1.193
	Median	3.11	3.50	3.21	3.21
	Min	1.56	1.70	1.10	1.10
	Max	8.10	7.52	7.42	8.10

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	57.03	57.02	56.38	56.81
	SD	8.495	9.128	8.768	8.767
	Median	56.00	55.80	56.30	56.15
	Min	35.70	35.80	32.80	32.80
	Max	78.10	79.20	74.10	79.20
Day4	n	69	71	70	210
	Mean	48.95	48.53	48.36	48.61
	SD	7.459	8.470	8.689	8.193
	Median	48.60	49.00	48.65	48.80
	Min	26.00	30.90	27.00	26.00
	Max	68.20	68.20	64.30	68.20
Day8	n	69	71	70	210
	Mean	50.39	50.17	48.78	49.78
	SD	7.381	7.889	8.311	7.867
	Median	50.10	50.00	47.75	49.65
	Min	24.10	31.60	27.00	24.10
	Max	67.60	65.00	66.50	67.60

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	49.83	51.09	50.28	50.41
	SD	8.109	8.178	9.671	8.654
	Median	50.45	50.30	48.10	49.50
	Min	31.20	31.70	33.20	31.20
	Max	68.80	71.10	74.30	74.30
Day29	n	67	70	70	207
	Mean	51.39	51.71	50.79	51.30
	SD	9.109	8.027	9.902	9.009
	Median	50.40	52.40	49.90	51.10
	Min	28.90	30.50	27.50	27.50
	Max	72.20	70.90	73.90	73.90
Day43	n	67	71	69	207
	Mean	52.66	53.79	52.28	52.92
	SD	8.340	8.099	9.237	8.553
	Median	52.70	53.90	52.10	52.90
	Min	27.80	33.40	33.90	27.80
	Max	78.40	73.90	71.60	78.40

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	54.94	55.60	54.85	55.13
	SD	9.275	6.878	9.243	8.494
	Median	55.00	55.00	54.65	55.00
	Min	32.30	44.10	30.50	30.50
	Max	79.90	76.00	74.70	79.90

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

Table 14.3.4.1.2.1
PF-06410293 Protocol B5381001
Laboratory Data Absolute Values - Safety Analysis Set
Parameter: Basophils (10^3/mm^3)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	0.06	0.06	0.06	0.06
	SD	0.040	0.039	0.040	0.039
	Median	0.04	0.04	0.05	0.05
	Min	0.00	0.00	0.00	0.00
	Max	0.20	0.20	0.20	0.20
Day4	n	69	71	70	210
	Mean	0.06	0.06	0.06	0.06
	SD	0.039	0.034	0.038	0.037
	Median	0.05	0.05	0.05	0.05
	Min	0.00	0.00	0.00	0.00
	Max	0.20	0.10	0.20	0.20
Day8	n	69	71	70	210
	Mean	0.06	0.06	0.06	0.06
	SD	0.039	0.041	0.038	0.039
	Median	0.05	0.05	0.05	0.05
	Min	0.00	0.00	0.00	0.00
	Max	0.20	0.20	0.20	0.20

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	0.06	0.06	0.06	0.06
	SD	0.040	0.039	0.035	0.038
	Median	0.05	0.05	0.05	0.05
	Min	0.00	0.00	0.00	0.00
	Max	0.20	0.20	0.10	0.20
Day29	n	67	70	70	207
	Mean	0.06	0.06	0.05	0.06
	SD	0.042	0.039	0.040	0.040
	Median	0.05	0.05	0.04	0.05
	Min	0.00	0.00	0.00	0.00
	Max	0.20	0.20	0.20	0.20
Day43	n	67	71	69	207
	Mean	0.07	0.06	0.06	0.06
	SD	0.040	0.038	0.038	0.039
	Median	0.05	0.05	0.05	0.05
	Min	0.02	0.00	0.00	0.00
	Max	0.20	0.20	0.20	0.20

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	0.06	0.06	0.06	0.06
	SD	0.039	0.035	0.041	0.038
	Median	0.04	0.05	0.05	0.05
	Min	0.00	0.00	0.00	0.00
	Max	0.20	0.10	0.20	0.20

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.

Table 14.3.4.1.2.1
PF-06410293 Protocol B5381001
Laboratory Data Absolute Values - Safety Analysis Set
Parameter: Basophils/Leukocytes (%)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	0.87	0.85	0.86	0.86
	SD	0.534	0.505	0.557	0.530
	Median	0.70	0.70	0.80	0.70
	Min	0.20	0.20	0.10	0.10
	Max	2.60	2.10	2.70	2.70
Day4	n	69	71	70	210
	Mean	0.98	0.94	0.95	0.96
	SD	0.523	0.467	0.463	0.483
	Median	0.80	0.80	0.90	0.80
	Min	0.20	0.30	0.20	0.20
	Max	2.30	2.50	2.20	2.50
Day8	n	69	71	70	210
	Mean	0.92	0.99	0.99	0.97
	SD	0.475	0.658	0.541	0.562
	Median	0.80	0.80	0.90	0.80
	Min	0.20	0.20	0.00	0.00
	Max	2.30	4.60	2.80	4.60

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	1.00	1.00	0.95	0.98
	SD	0.529	0.545	0.538	0.535
	Median	0.80	0.80	0.80	0.80
	Min	0.30	0.30	0.20	0.20
	Max	2.20	2.80	2.60	2.80
Day29	n	67	70	70	207
	Mean	0.97	0.97	0.93	0.96
	SD	0.621	0.536	0.536	0.563
	Median	0.80	0.90	0.80	0.80
	Min	0.20	0.20	0.10	0.10
	Max	3.00	2.70	2.70	3.00
Day43	n	67	71	69	207
	Mean	1.04	1.00	0.97	1.00
	SD	0.583	0.655	0.549	0.596
	Median	0.90	0.80	0.90	0.80
	Min	0.30	0.10	0.20	0.10
	Max	3.00	2.80	2.60	3.00

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	0.88	0.90	0.94	0.91
	SD	0.551	0.462	0.576	0.529
	Median	0.80	0.80	0.80	0.80
	Min	0.10	0.20	0.10	0.10
	Max	2.80	2.20	2.80	2.80

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	0.15	0.18	0.18	0.17
	SD	0.117	0.129	0.143	0.130
	Median	0.11	0.15	0.15	0.14
	Min	0.00	0.00	0.00	0.00
	Max	0.60	0.60	0.73	0.73
Day4	n	69	71	70	210
	Mean	0.18	0.21	0.20	0.20
	SD	0.124	0.140	0.135	0.133
	Median	0.15	0.19	0.17	0.17
	Min	0.00	0.00	0.00	0.00
	Max	0.70	0.80	0.70	0.80
Day8	n	69	71	70	210
	Mean	0.17	0.17	0.18	0.17
	SD	0.111	0.117	0.133	0.121
	Median	0.13	0.13	0.12	0.13
	Min	0.00	0.00	0.00	0.00
	Max	0.54	0.60	0.60	0.60

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	0.19	0.20	0.19	0.19
	SD	0.131	0.134	0.139	0.134
	Median	0.18	0.19	0.13	0.18
	Min	0.00	0.00	0.03	0.00
	Max	0.59	0.71	0.55	0.71
Day29	n	67	70	70	207
	Mean	0.19	0.18	0.21	0.19
	SD	0.128	0.114	0.141	0.128
	Median	0.17	0.17	0.19	0.17
	Min	0.00	0.00	0.00	0.00
	Max	0.58	0.50	0.60	0.60
Day43	n	67	71	69	207
	Mean	0.19	0.19	0.19	0.19
	SD	0.132	0.146	0.145	0.141
	Median	0.15	0.15	0.16	0.15
	Min	0.00	0.00	0.03	0.00
	Max	0.67	0.90	0.90	0.90

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	0.17	0.21	0.19	0.19
	SD	0.112	0.137	0.157	0.137
	Median	0.13	0.16	0.15	0.15
	Min	0.00	0.00	0.00	0.00
	Max	0.48	0.60	0.80	0.80

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

Table 14.3.4.1.2.1
PF-06410293 Protocol B5381001
Laboratory Data Absolute Values - Safety Analysis Set
Parameter: Eosinophils/Leukocytes (%)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	2.51	2.76	2.85	2.71
	SD	1.641	2.064	2.131	1.955
	Median	2.20	2.20	2.35	2.20
	Min	0.50	0.30	0.50	0.30
	Max	7.70	11.40	11.50	11.50
Day4	n	69	71	70	210
	Mean	3.16	3.45	3.40	3.34
	SD	1.610	2.241	2.099	1.999
	Median	2.70	2.80	2.75	2.70
	Min	0.80	0.90	0.90	0.80
	Max	8.10	11.80	10.90	11.80
Day8	n	69	71	70	210
	Mean	2.87	3.01	3.08	2.99
	SD	1.563	2.019	2.001	1.868
	Median	2.70	2.50	2.50	2.50
	Min	0.40	0.30	0.50	0.30
	Max	7.30	8.90	10.20	10.20

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	3.38	3.34	3.18	3.30
	SD	2.172	2.313	2.219	2.227
	Median	2.90	2.80	2.60	2.80
	Min	0.40	0.70	0.40	0.40
	Max	9.60	12.10	10.20	12.10
Day29	n	67	70	70	207
	Mean	3.25	3.18	3.52	3.32
	SD	1.903	1.994	2.297	2.069
	Median	2.80	2.75	2.90	2.80
	Min	0.60	0.40	0.50	0.40
	Max	8.60	8.70	10.90	10.90
Day43	n	67	71	69	207
	Mean	3.10	3.18	3.17	3.15
	SD	2.094	2.196	2.036	2.101
	Median	2.40	2.60	2.80	2.60
	Min	0.30	0.80	0.40	0.30
	Max	11.70	11.60	11.50	11.70

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	2.83	3.27	3.15	3.09
	SD	1.855	1.914	2.278	2.024
	Median	2.30	2.80	2.55	2.50
	Min	0.30	0.50	0.40	0.30
	Max	7.80	7.90	12.80	12.80

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

Table 14.3.4.1.2.1
PF-06410293 Protocol B5381001
Laboratory Data Absolute Values - Safety Analysis Set
Parameter: Monocytes (10^3/mm^3)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	0.42	0.47	0.45	0.45
	SD	0.118	0.157	0.157	0.146
	Median	0.40	0.44	0.41	0.42
	Min	0.20	0.20	0.20	0.20
	Max	0.70	1.00	1.10	1.10
Day4	n	69	71	70	210
	Mean	0.40	0.41	0.41	0.41
	SD	0.109	0.123	0.125	0.119
	Median	0.39	0.40	0.40	0.40
	Min	0.19	0.20	0.20	0.19
	Max	0.70	0.80	0.80	0.80
Day8	n	69	71	70	210
	Mean	0.40	0.44	0.41	0.42
	SD	0.116	0.158	0.129	0.137
	Median	0.38	0.40	0.40	0.40
	Min	0.20	0.23	0.10	0.10
	Max	0.80	1.17	0.90	1.17

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	0.42	0.45	0.44	0.44
	SD	0.134	0.151	0.147	0.144
	Median	0.40	0.42	0.40	0.40
	Min	0.20	0.20	0.20	0.20
	Max	0.90	1.10	0.90	1.10
Day29	n	67	70	70	207
	Mean	0.46	0.44	0.45	0.45
	SD	0.142	0.156	0.179	0.159
	Median	0.42	0.40	0.40	0.40
	Min	0.20	0.20	0.20	0.20
	Max	0.90	0.90	1.10	1.10
Day43	n	67	71	69	207
	Mean	0.44	0.45	0.46	0.45
	SD	0.139	0.150	0.182	0.158
	Median	0.40	0.40	0.41	0.40
	Min	0.20	0.20	0.20	0.20
	Max	0.90	1.00	1.30	1.30

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	0.42	0.47	0.46	0.45
	SD	0.112	0.165	0.160	0.149
	Median	0.40	0.46	0.46	0.44
	Min	0.20	0.20	0.10	0.10
	Max	0.70	1.20	0.90	1.20

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

Table 14.3.4.1.2.1
PF-06410293 Protocol B5381001
Laboratory Data Absolute Values - Safety Analysis Set
Parameter: Monocytes/Leukocytes (%)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	6.88	7.34	7.03	7.08
	SD	1.545	2.159	1.861	1.876
	Median	6.70	7.20	6.55	6.75
	Min	3.90	3.50	3.60	3.50
	Max	10.90	14.30	11.90	14.30
Day4	n	69	71	70	210
	Mean	7.05	7.07	7.12	7.08
	SD	1.734	1.698	1.746	1.718
	Median	6.60	6.90	6.85	6.80
	Min	4.30	3.50	4.00	3.50
	Max	12.50	12.10	12.20	12.50
Day8	n	69	71	70	210
	Mean	7.00	7.61	7.08	7.23
	SD	1.617	2.594	1.801	2.061
	Median	6.70	7.00	6.80	6.80
	Min	4.40	3.80	4.70	3.80
	Max	12.90	18.80	13.70	18.80

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	7.27	7.58	7.48	7.44
	SD	1.833	2.184	2.063	2.029
	Median	7.00	7.30	7.30	7.10
	Min	3.90	3.60	4.50	3.60
	Max	13.80	15.30	14.50	15.30
Day29	n	67	70	70	207
	Mean	7.67	7.69	7.60	7.65
	SD	2.056	2.218	2.359	2.206
	Median	7.40	7.35	7.00	7.20
	Min	4.20	3.90	4.30	3.90
	Max	13.60	14.10	16.50	16.50
Day43	n	67	71	69	207
	Mean	7.42	7.63	7.77	7.60
	SD	1.699	2.077	2.160	1.988
	Median	7.40	7.50	7.10	7.40
	Min	4.60	3.70	5.20	3.70
	Max	11.40	14.80	18.00	18.00

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

Table 14.3.4.1.2.1
PF-06410293 Protocol B5381001
Laboratory Data Absolute Values - Safety Analysis Set
Parameter: Monocytes/Leukocytes (%)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	6.99	7.70	7.55	7.42
	SD	1.399	2.288	2.204	2.021
	Median	6.80	7.30	7.20	7.10
	Min	4.40	4.10	3.80	3.80
	Max	10.70	16.40	14.10	16.40

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

Table 14.3.4.1.2.1
PF-06410293 Protocol B5381001
Laboratory Data Absolute Values - Safety Analysis Set
Parameter: Bilirubin (mg/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	0.71	0.69	0.65	0.69
	SD	0.342	0.310	0.282	0.311
	Median	0.60	0.70	0.60	0.60
	Min	0.20	0.20	0.30	0.20
	Max	1.80	2.00	1.70	2.00
Day4	n	69	71	70	210
	Mean	0.72	0.69	0.62	0.68
	SD	0.327	0.282	0.274	0.297
	Median	0.60	0.60	0.60	0.60
	Min	0.30	0.30	0.10	0.10
	Max	1.70	1.80	1.80	1.80
Day8	n	69	71	70	210
	Mean	0.77	0.70	0.63	0.70
	SD	0.319	0.291	0.257	0.294
	Median	0.70	0.70	0.60	0.60
	Min	0.40	0.30	0.20	0.20
	Max	2.00	1.70	1.70	2.00

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	0.67	0.66	0.59	0.64
	SD	0.304	0.379	0.259	0.319
	Median	0.65	0.60	0.60	0.60
	Min	0.20	0.20	0.20	0.20
	Max	2.30	2.70	1.40	2.70
Day29	n	67	70	70	207
	Mean	0.68	0.70	0.62	0.67
	SD	0.363	0.349	0.262	0.328
	Median	0.60	0.60	0.60	0.60
	Min	0.20	0.20	0.20	0.20
	Max	2.40	1.80	1.40	2.40
Day43	n	67	71	69	207
	Mean	0.70	0.66	0.64	0.67
	SD	0.346	0.278	0.296	0.307
	Median	0.60	0.60	0.60	0.60
	Min	0.20	0.20	0.20	0.20
	Max	2.10	1.60	2.00	2.10

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	0.63	0.66	0.59	0.63
	SD	0.320	0.305	0.282	0.302
	Median	0.60	0.60	0.60	0.60
	Min	0.20	0.20	0.20	0.20
	Max	1.80	1.50	1.80	1.80

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	23.17	24.66	24.41	24.09
	SD	6.338	7.376	7.544	7.107
	Median	22.00	23.00	24.00	23.00
	Min	13.00	13.00	13.00	13.00
	Max	44.00	48.00	57.00	57.00
Day4	n	69	71	70	210
	Mean	19.81	20.54	21.00	20.45
	SD	4.519	5.949	5.440	5.339
	Median	20.00	20.00	20.00	20.00
	Min	12.00	12.00	12.00	12.00
	Max	36.00	45.00	43.00	45.00
Day8	n	69	71	70	210
	Mean	20.41	21.97	22.51	21.64
	SD	4.397	6.708	4.892	5.483
	Median	20.00	21.00	23.00	21.00
	Min	12.00	13.00	14.00	12.00
	Max	29.00	57.00	47.00	57.00

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	22.12	34.37	22.94	26.57
	SD	5.391	85.596	5.604	50.290
	Median	21.00	22.00	22.00	22.00
	Min	12.00	13.00	13.00	12.00
	Max	35.00	740.00	44.00	740.00
Day29	n	67	70	70	207
	Mean	23.01	27.89	28.83	26.63
	SD	5.999	12.240	28.910	18.657
	Median	22.00	25.00	23.50	23.00
	Min	11.00	14.00	13.00	11.00
	Max	52.00	85.00	245.00	245.00
Day43	n	67	71	69	207
	Mean	24.01	27.45	27.41	26.32
	SD	7.254	10.803	14.819	11.470
	Median	23.00	25.00	25.00	24.00
	Min	13.00	15.00	14.00	13.00
	Max	65.00	83.00	112.00	112.00

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	25.03	27.70	28.29	27.02
	SD	6.905	9.188	24.317	15.525
	Median	24.00	25.00	24.00	24.00
	Min	14.00	14.00	14.00	14.00
	Max	48.00	58.00	214.00	214.00

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

Table 14.3.4.1.2.1
PF-06410293 Protocol B5381001
Laboratory Data Absolute Values - Safety Analysis Set
Parameter: Alanine Aminotransferase (U/L)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	21.90	25.58	24.51	24.01
	SD	8.347	13.762	8.970	10.726
	Median	21.00	23.00	24.00	23.00
	Min	5.00	9.00	11.00	5.00
	Max	41.00	75.00	62.00	75.00
Day4	n	69	71	70	210
	Mean	20.54	23.55	23.39	22.50
	SD	8.934	13.316	7.694	10.335
	Median	20.00	20.00	22.00	20.00
	Min	6.00	8.00	11.00	6.00
	Max	52.00	68.00	45.00	68.00
Day8	n	69	71	70	210
	Mean	22.65	26.17	26.77	25.21
	SD	9.762	15.478	10.433	12.266
	Median	21.00	22.00	25.00	23.50
	Min	7.00	8.00	13.00	7.00
	Max	50.00	97.00	92.00	97.00

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	22.51	32.13	25.17	26.68
	SD	10.039	36.939	10.062	23.322
	Median	20.00	23.00	24.00	23.00
	Min	5.00	9.00	13.00	5.00
	Max	60.00	297.00	79.00	297.00
Day29	n	67	70	70	207
	Mean	23.19	30.04	28.21	27.21
	SD	10.005	18.072	25.517	19.180
	Median	22.00	26.00	24.00	24.00
	Min	5.00	10.00	12.00	5.00
	Max	52.00	102.00	215.00	215.00
Day43	n	67	71	69	207
	Mean	22.96	28.73	26.71	26.19
	SD	9.605	14.252	12.039	12.335
	Median	22.00	24.00	24.00	23.00
	Min	6.00	8.00	11.00	6.00
	Max	64.00	70.00	92.00	92.00

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	23.25	29.56	27.80	26.90
	SD	9.875	15.743	19.247	15.625
	Median	22.00	26.00	24.50	24.00
	Min	6.00	8.00	11.00	6.00
	Max	54.00	82.00	170.00	170.00

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

Table 14.3.4.1.2.1
PF-06410293 Protocol B5381001
Laboratory Data Absolute Values - Safety Analysis Set
Parameter: Alkaline Phosphatase (U/L)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	67.99	70.94	72.01	70.33
	SD	17.081	19.206	19.065	18.476
	Median	67.00	68.00	71.00	68.00
	Min	42.00	29.00	37.00	29.00
	Max	119.00	125.00	124.00	125.00
Day4	n	69	71	70	210
	Mean	65.13	67.03	68.61	66.93
	SD	15.712	16.946	17.619	16.764
	Median	62.00	64.00	67.00	64.00
	Min	37.00	24.00	37.00	24.00
	Max	111.00	119.00	116.00	119.00
Day8	n	69	71	70	210
	Mean	66.07	67.52	69.59	67.73
	SD	15.945	17.442	17.634	17.010
	Median	63.00	64.00	66.00	64.00
	Min	41.00	27.00	36.00	27.00
	Max	116.00	131.00	118.00	131.00

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	65.88	69.23	68.84	68.00
	SD	16.267	18.817	16.876	17.354
	Median	64.50	66.00	68.00	66.00
	Min	40.00	32.00	39.00	32.00
	Max	112.00	133.00	116.00	133.00
Day29	n	67	70	70	207
	Mean	65.42	68.19	70.84	68.19
	SD	16.631	17.798	18.112	17.592
	Median	64.00	66.50	68.50	66.00
	Min	41.00	27.00	36.00	27.00
	Max	110.00	139.00	114.00	139.00
Day43	n	67	71	69	207
	Mean	66.60	70.85	72.78	70.12
	SD	16.672	18.850	20.523	18.852
	Median	63.00	68.00	71.00	68.00
	Min	42.00	23.00	38.00	23.00
	Max	115.00	138.00	154.00	154.00

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	68.04	71.10	71.87	70.35
	SD	17.209	19.856	19.803	18.990
	Median	68.00	69.00	69.50	69.00
	Min	42.00	23.00	40.00	23.00
	Max	120.00	143.00	134.00	143.00

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

Table 14.3.4.1.2.1
PF-06410293 Protocol B5381001
Laboratory Data Absolute Values - Safety Analysis Set
Parameter: Protein (g/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	7.21	7.28	7.19	7.23
	SD	0.395	0.408	0.378	0.394
	Median	7.20	7.20	7.20	7.20
	Min	6.40	6.20	6.40	6.20
	Max	8.20	8.30	8.40	8.40
Day4	n	69	71	70	210
	Mean	7.05	7.08	6.99	7.04
	SD	0.391	0.410	0.399	0.400
	Median	7.10	7.10	7.00	7.10
	Min	6.30	6.00	6.00	6.00
	Max	8.00	8.30	8.00	8.30
Day8	n	69	71	70	210
	Mean	7.13	7.14	7.08	7.12
	SD	0.416	0.383	0.391	0.396
	Median	7.10	7.10	7.10	7.10
	Min	6.40	6.10	6.10	6.10
	Max	8.10	8.00	8.20	8.20

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	7.15	7.22	7.08	7.15
	SD	0.372	0.395	0.363	0.379
	Median	7.10	7.20	7.10	7.10
	Min	6.30	5.90	6.00	5.90
	Max	8.00	8.30	8.10	8.30
Day29	n	67	70	70	207
	Mean	7.21	7.30	7.24	7.25
	SD	0.318	0.391	0.380	0.366
	Median	7.20	7.30	7.20	7.20
	Min	6.70	6.40	6.20	6.20
	Max	8.20	8.40	8.00	8.40
Day43	n	67	71	69	207
	Mean	7.33	7.33	7.23	7.30
	SD	0.316	0.406	0.349	0.361
	Median	7.30	7.30	7.20	7.30
	Min	6.70	6.20	6.60	6.20
	Max	8.20	8.30	8.30	8.30

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	7.29	7.32	7.20	7.27
	SD	0.408	0.432	0.397	0.414
	Median	7.30	7.30	7.20	7.20
	Min	6.40	6.30	6.30	6.30
	Max	8.20	8.40	8.30	8.40

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

Table 14.3.4.1.2.1
PF-06410293 Protocol B5381001
Laboratory Data Absolute Values - Safety Analysis Set
Parameter: Albumin (g/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	4.57	4.57	4.55	4.56
	SD	0.252	0.239	0.209	0.233
	Median	4.60	4.60	4.60	4.60
	Min	4.00	3.80	4.00	3.80
	Max	5.10	5.30	5.00	5.30
Day4	n	69	71	70	210
	Mean	4.42	4.41	4.40	4.41
	SD	0.209	0.248	0.253	0.237
	Median	4.40	4.40	4.40	4.40
	Min	4.00	3.50	3.60	3.50
	Max	5.00	5.00	5.10	5.10
Day8	n	69	71	70	210
	Mean	4.50	4.45	4.46	4.47
	SD	0.235	0.208	0.234	0.226
	Median	4.50	4.40	4.45	4.50
	Min	4.00	3.70	4.00	3.70
	Max	5.00	4.90	5.20	5.20

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	4.52	4.51	4.49	4.51
	SD	0.228	0.272	0.235	0.245
	Median	4.50	4.50	4.50	4.50
	Min	4.00	3.70	3.90	3.70
	Max	4.90	5.10	5.10	5.10
Day29	n	67	70	70	207
	Mean	4.53	4.55	4.57	4.55
	SD	0.247	0.226	0.271	0.248
	Median	4.50	4.60	4.60	4.60
	Min	4.10	3.80	4.00	3.80
	Max	5.10	5.10	5.20	5.20
Day43	n	67	71	69	207
	Mean	4.59	4.55	4.54	4.56
	SD	0.194	0.229	0.219	0.215
	Median	4.60	4.50	4.50	4.50
	Min	4.20	3.70	4.00	3.70
	Max	5.00	5.00	5.10	5.10

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	4.56	4.54	4.50	4.53
	SD	0.238	0.230	0.242	0.237
	Median	4.60	4.50	4.50	4.50
	Min	4.00	4.00	4.00	4.00
	Max	5.20	5.10	5.20	5.20

Baseline is defined as the most recent measurement prior to dosing.
If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
If two tests have equal distance to the target day, then the later one will be used.
Study Day is based on time windows.
Lab results in standard units have been used in the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:16)